Biochips

Biochips

Global Biochips Market to Reach US$44.8 Billion by 2030

The global market for Biochips estimated at US$19.3 Billion in the year 2023, is expected to reach US$44.8 Billion by 2030, growing at a CAGR of 12.8% over the analysis period 2023-2030. DNA Chip, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$14.7 Billion by the end of the analysis period. Growth in the Lab-on-a-Chip segment is estimated at 13.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.0 Billion While China is Forecast to Grow at 14.8% CAGR

The Biochips market in the U.S. is estimated at US$7.0 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 14.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.7% and 11.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.

Global Biochips Market - Key Trends & Drivers Summarized

Biochips are miniature laboratories that can perform hundreds or thousands of simultaneous biochemical reactions, offering vast potential in various fields such as medical diagnostics, genomics, and drug development. These tiny devices, typically fabricated from silicon or glass substrates, integrate microarrays and microfluidics to analyze biological materials with high precision and speed. Biochips can analyze DNA, RNA, proteins, and small molecules, making them essential tools in genetic sequencing, gene expression profiling, and biomarker detection. In clinical diagnostics, biochips enable rapid and accurate detection of diseases by identifying specific genetic markers or pathogens, thus facilitating early diagnosis and personalized treatment plans. Their ability to conduct large-scale screenings efficiently and cost-effectively has revolutionized biomedical research and clinical practices.

Technological advancements have significantly enhanced the capabilities and applications of biochips. Innovations in microfabrication techniques have led to the development of more sophisticated and sensitive biochips, capable of detecting even minute quantities of biological substances. The integration of advanced sensors and imaging systems with biochips has improved their analytical performance, enabling real-time monitoring and high-throughput analysis. Additionally, the advent of lab-on-a-chip technology, which miniaturizes and integrates all laboratory functions on a single chip, has expanded the application scope of biochips beyond traditional research labs to point-of-care diagnostics and field applications. This technology allows for the rapid, on-site analysis of samples, which is particularly beneficial in resource-limited settings and for real-time disease outbreak monitoring.

The growth in the biochips market is driven by several factors. The increasing prevalence of chronic and infectious diseases has heightened the demand for advanced diagnostic tools, propelling the adoption of biochips in clinical settings. Biochips are being increasingly used in the development of personalized and targeted drugs for treating various cancers. Increasing interest among consumers in maintaining healthy lifestyles has also been resulting in demand growth for the chips.  Technological advancements in microarray and microfluidics technology are enhancing the efficiency and accuracy of biochips, encouraging their widespread use in genomics and proteomics research. The rising focus on personalized medicine and the need for precise and rapid diagnostic solutions are also significant drivers, as biochips offer the capability to tailor treatments based on individual genetic profiles. Furthermore, government funding and initiatives supporting genomics research and the development of advanced diagnostic technologies are boosting market growth. The expanding applications of biochips in environmental monitoring, food safety testing, and bioterrorism detection are opening new avenues for their use, further driving market expansion. Together, these factors are fostering a dynamic and rapidly growing market for biochips, presenting significant opportunities for innovation and development in the field of biotechnology.

Select Competitors (Total 69 Featured) -

• Eppendorf AG
• Fluidigm Corporation
• F. Hoffmann-La Roche AG
• IntegraGen SA
• Agendia NV
• Ocimum Biosolutions Ltd.
• Analis SA/NV
• Empire Genomics LLC
• Mobidiag
• AVIVA BioSciences Corporation
• Little Things Factory GmbH
• IDEX Health & Science LLC
• Arround Inc.
• As One Corporation
• Cala Del Forte

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.